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PAspirin Resistance
Treatment of Aspirin-Resistant Patients With
Omega-3 Fatty Acids Versus Aspirin Dose Escalation
Eli I. Lev, MD,*† Alejandro Solodky, MD,*† Naama Harel,* Aviv Mager, MD,*† David Brosh, MD,*†
Abid Assali, MD,*† Milton Roller, MD,*† Alexander Battler, MD,*† Neal S. Kleiman, MD,‡
Ran Kornowski, MD*†
Petah Tikva and Tel-Aviv, Israel; and Houston, Texas
Objectives The aim of this study was to evaluate whether addition of omega-3 fatty acids or increase in aspirin dose im-
proves response to low-dose aspirin among patients who are aspirin resistant.
Background Low response to aspirin has been associated with adverse cardiovascular events. However, there is no estab-
lished therapeutic approach to overcome aspirin resistance. Omega-3 fatty acids decrease the availability of
platelet arachidonic acid (AA) and indirectly thromboxane A2 formation.
Methods Patients (n  485) with stable coronary artery disease taking low-dose aspirin (75 to 162 mg) for at least 1
week were screened for aspirin response with the VerifyNow Aspirin assay (Accumetrics, San Diego, California). Fur-
ther testing was performed by platelet aggregation. Aspirin resistance was defined by 2 of 3 criteria: VerifyNow
score 550, 0.5-mg/ml AA-induced aggregation 20%, and 10-mol/l adenosine diphosphate (ADP)-induced aggre-
gation 70%. Thirty patients (6.2%) were found to be aspirin resistant and randomized to receive either low-dose
aspirin  omega-3 fatty acids (4 capsules daily) or aspirin 325 mg daily. After 30 days of treatment patients
were re-tested.
Results Both groups (n  15 each) had similar clinical characteristics. After treatment significant reductions in AA- and
ADP-induced aggregation and the VerifyNow score were observed in both groups. Plasma levels of thromboxane
B2 were also reduced in both groups (56.8% reduction in the omega-3 fatty acids group, and 39.6% decrease in
the aspirin group). Twelve patients (80%) who received omega-3 fatty acids and 11 patients (73%) who received
aspirin 325 mg were no longer aspirin resistant after treatment.
Conclusions Treatment of aspirin-resistant patients by adding omega-3 fatty acids or increasing the aspirin dose seems to
improve response to aspirin and effectively reduces platelet reactivity. (J Am Coll Cardiol 2010;55:114–21)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.039r
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cn recent years it has become apparent that the biologic
esponse to aspirin therapy is not uniform; rather, there is
ide interindividual variability in the response to aspirin
1,2). The prevalence of low response or “resistance” to the
ntiplatelet effects of aspirin is estimated to be1% to 45%,
epending on the assay used, cutoff value chosen, and
opulation tested (3–8). Low response to aspirin has been
ssociated with adverse clinical outcomes in patients with
ardiovascular disease or cardiovascular risk factors (2,4,7,9)
nd with an increase in markers of myonecrosis after
ercutaneous coronary intervention (PCI) (5,6). Further-
ore, 2 recent meta-analyses encompassing 15 to 20 studies
nd totaling almost 3,000 patients showed that aspirin
rom the *Cardiology Department, Rabin Medical Center, Petah Tikva, Israel;
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; and them
Methodist DeBakey Heart Center, The Methodist Hospital, Houston, Texas.
Manuscript received June 12, 2009, accepted August 10, 2009.esistance was associated with an odds ratio of almost 4 for
evelopment of cardiovascular events (10,11). Despite the
merging clinical evidence, there is no established treatment
aradigm for the management of patients who are resistant
o the effects of aspirin.
One potential approach to manage aspirin resistance is to
ncrease the drug dose. Most patients receiving long-term
spirin therapy after an acute myocardial infarction (MI) or
CI are treated with low-dose aspirin (75 to 162 mg/day).
herefore, resistant patients could potentially be treated by
ncreasing the dose to 325 mg/day. However, the Anti-
hrombotic Trialists’ Collaboration meta-analysis has
hown that there is no difference in clinical efficacy for
revention of vascular events when comparing aspirin doses
f 75 to 325 mg and even higher doses (12). Conversely,
ee et al. (13) have shown that, among patients with stable
oronary artery disease (CAD), low aspirin dose (80 to 100
g) was associated with the highest prevalence of resistance
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January 12, 2010:114–21 Omega-3 Fatty Acid Treatment for Aspirin Resistanceompared with higher doses. Furthermore, Gurbel et al.
14) reported dose-dependent effects of aspirin on platelet
unction when using assays not based on arachidonic acid
AA). It is not known, however, whether increasing the
ose in resistant patients taking low-dose aspirin would
mprove the response to the drug.
Another possible approach to the management of aspirin
esistance is to add an additional substance that would
nhibit the cyclooxygenase (COX)-1 pathway. Omega-3
atty acids, which are components of dietary fish oil, might
ulfill this role. Ingestion of fish oils leads to replacement of
-6 fatty acids (such as AA) by n-3 fatty acids in the cell
embranes of various cells (15,16). In platelets this process
eads to a reduction in the availability of platelet membrane
A, along with an increase in eicosapentaenoic acid (EPA)
15). The latter substance can compete with AA as a sub-
trate of the COX-1 pathway. The net effect is an increase
n the ratio of EPA to AA and indirectly a reduction in
hromboxane A2 formation from AA (15,16). Studies of
ntiplatelet effects of fish oil, however, have been inconsis-
ent (16,17). In patients naïve to aspirin, a daily dose of 3 to
g omega-3 fatty acids given over several weeks seems to
ave mild antiplatelet effects, such as weak inhibition of
ollagen-induced platelet aggregation and mild prolonga-
ion of bleeding time (16–18).
Recently Larson et al. (19) reported that omega-3 fatty
cids alone had no significant effect on platelet aggregation
ut when combined with aspirin had a synergistic inhibitory
ffect. It should be noted that addition of omega-3 fatty
cids (1 to 4 g/day) to aspirin in patients with cardiovascular
isease has not been associated with an increased risk of
leeding complications (20,21). Given the mechanism of
ction of omega-3 fatty acids and the report by Larson et al.
19), we hypothesized that omega-3 fatty acids might act in
ynergy with aspirin among patients with low response to
spirin. Therefore, our aim was to evaluate whether adding
mega-3 fatty acids or increasing the aspirin dose would
mprove the response to low-dose aspirin among patients
ho are aspirin resistant.
ethods
atients. Stable patients with CAD, ages 18 to 80 years,
ho have been treated with aspirin at a dose of 75 to 162 mg
or at least 1 week were included. Exclusion criteria were PCI
r an acute coronary syndrome within 1 month of enrollment;
reatment with glycoprotein IIb/IIIa inhibitors or thrombolytic
gents within 1 month of enrollment; concomitant treatment
ith omega-3 fatty acid-containing products; concomitant
reatment with ibuprofen, naproxene, or warfarin; thrombo-
ytopenia (100  103 cells/mm3); anemia (hemoglobin
10 g/dl); or renal insufficiency (creatinine 2.5 mg/dl).
he study was approved by the Investigational Review
oard (Helsinki committee) of the Rabin Medical Center,srael, and all subjects provided written informed consent. pcreening for aspirin resistance.
he VerifyNow Aspirin assay
Accumetrics, San Diego, Cali-
ornia) was used for the purpose
f screening for aspirin resis-
ance. This assay is a point-of
are, turbidometric-based system
hat uses citrate-anticoagulated
lood and cartridges containing
brinogen-coated beads and AA
s the platelet agonist. Results
re expressed as aspirin reaction
nits (ARU). According to the
anufacturer’s recommendation,
cutoff of 550 ARU indicates
esistance to the antiplatelet ef-
ects of aspirin. However, from
ur previous cohort of 150 pa-
ients (5), a cutoff level of 550 ARU had a sensitivity of 70%
nd specificity of 90% for identification of aspirin resistance
hen compared with AA-induced platelet aggregation.
herefore we used a cutoff level of 500 ARU for screening,
hich was associated with sensitivity of 90% and specificity
f 75% in our previous cohort. Patients with an ARU 500
nderwent further testing by turbidimetric platelet aggrega-
ion in response to AA and adenosine diphosphate (ADP)
Fig. 1). Our aim was to identify 30 patients with aspirin
esistance (Fig. 1).
efinition of aspirin resistance. Aspirin resistance was
efined by the presence of at least 2 of the following 3 criteria:
.5-mg/ml AA-induced platelet aggregation20%, 10-mol/l
DP-induced aggregation 70%, and VerifyNow ARU
550 (in contrast to the screening process in which an ARU
500 was used as the cutoff) (5). In case of concomitant
reatment with clopidogrel (approximately 5% of the patients
creened) aspirin resistance was defined on the basis of 2 of 2
riteria (AA-induced aggregation and VerifyNow Aspirin).
andomization of aspirin-resistant patients. Patients
ound to be aspirin resistant were randomized 1:1 into 2
roups (n 15 each): 1) treatment with the original dose of
spirin and, in addition, omega-3 fatty acids—4 capsules/
ay taken 2 in the morning and 2 in the evening, each
apsule containing 360 mg EPA and 240 mg DHA (Omega
ax 3, SupHerb, Israel), for a period of 30 days; and 2)
reatment with aspirin 325 mg daily for a period of 30 days.
In addition, a control group of 15 patients was randomly
elected from the patients with an ARU 500 who did not
ulfill the criteria for aspirin resistance (Fig. 1). These
atients continued to receive the same treatment (including
he original aspirin dose), without change. The 2 study
roups and control group underwent testing for response to
spirin after 30 days of treatment with the corresponding
egimen.
ollow-up phase. All 30 patients included in the 2 treat-
ent groups were invited to participate in a follow-up phase
Abbreviations
and Acronyms
AA  arachidonic acid
ADP  adenosine
diphosphate
ARU  aspirin reaction
units
CAD  coronary artery
disease
COX  cyclooxygenase
EPA  eicosapentaenoic
acid
MI  myocardial infarction
PCI  percutaneous
coronary intervention
TXB2  thromboxane B2erformed approximately 1 year (13  4 months) after the
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dentical to the first baseline sample, after discontinuing the
orresponding treatment (omega-3 fatty acids supplemen-
ation or high-dose aspirin) and reverting back to the
riginal low-dose aspirin. The purpose of this phase was to
xamine the stability of aspirin response at the baseline
onditions. Some of the patients were treated with low-dose
spirin when contacted; others were asked to take low-dose
spirin (without omega-3 fatty acids) for a period of at least
week before testing. A total of 24 patients (12 in each
roup) participated in the follow-up phase. The other 6
atients were not available or interested in participating or
ad significant changes in their medical management.
lood sampling. All blood samples were obtained from an
ntecubital vein, with a 21-gauge needle, and collected in
ubes containing 3.2% citrate. The tubes were filled to
apacity and gently mixed. The blood samples were pro-
essed within 2 h of blood collection.
valuation of response to aspirin. In addition to the
erifyNow Aspirin assay, the following tests were per-
ormed at all time points.
IGHT TRANSMITTANCE (TURBIDIMETRIC) PLATELET AGGRE-
ATION. Light transmittance (turbidimetric) platelet aggre-
ation was performed in platelet-rich plasma with a platelet
ount adjusted to approximately 250  103/mm3. Platelets
ere stimulated with 0.5 mg/ml (1.6 mmol/l) AA and 5-
nd 10-mol/l ADP. Aggregation was performed with a
ioData PAP-4 platelet aggregometer (BioData, Horsham,
485 patients with CA
62 pa
30 patients with aspirin resistance (
≥ 2 of 3 criteria for aspirin resistance
Agg
Aspirin 325 mg 
15 patients
Omega-3 fat
15 patien
Randomization
30 day f/u tests 30 day f/u t
30 day treatment
Figure 1 Algorithm of the Study
We aimed to identify 30 patients with aspirin resistance. Patients with stable coro
Aspirin assay (Accumetrics). Sixty-two patients (12.8%) had an aspirin reaction uni
patients (6.2%) were found to be resistant and were randomized to 1 of the 2 treaennsylvania). The extent of aggregation was defined as the vaximal light transmission 6 min after addition of the
gonist, with platelet-poor plasma used as reference.
LASMA LEVELS OF THROMBOXANE B2 (TXB2). Plasma levels
f TXB2 were determined from frozen plasma samples
kept at 70°C until testing), with an enzyme immunoas-
ay, according to the manufacturer’s instructions (Cayman
hemical Co., Ann Arbor, Michigan).
ompliance at the initial interview. Compliance to aspi-
in (taken 1 week) was verified separately by the patient’s
ttending physician, study nurse, and study physician. In
ases of uncertainty, patients were not enrolled. Two patients
ith an ARU 500 had an exceptionally high level of
A-induced aggregation (40%) and were asked to be re-
ested after 1 week of aspirin treatment (1 patient became
esponsive and was withdrawn from the study; the other
emained resistant but with lower levels of AA-induced aggre-
ation than originally measured). In the 2 study groups,
ompliance to the specific regimen was verified by phone call
fter 2 weeks of treatment.
tatistical analysis. Continuous variables are presented as
ean  SD. Comparisons between aspirin-resistant and
esponsive patients (Table 1) were performed by unpaired
tudent t tests and chi-square tests for continuous and
ategorical variables, respectively. Intragroup comparisons
between the 2 time points) were performed by paired
tudent t tests. Intergroup comparisons (between the 2
tudy groups) of the magnitude of change induced by the
pecific treatment were performed by 2-factor analysis of
ated with low-dose aspirin
VerifyNow ARU > 500
s (12.8%)
) 32 patients (6.6%)
< 2 criteria for aspirin resistance
on studies
ids
30 day f/u tests
15 randomly selected
patients for “control group”
rtery disease (CAD) (n  485) were screened for resistance by the VerifyNow
) score 500 and underwent further testing by platelet aggregation. Thirty
groups. They were re-tested after 30 days of treatment. f/u  follow-up.D tre
tient
6.2%
regati
ty ac
ts
ests
nary a
t (ARU
tmentariance with repeated measures (for group- and time-
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January 12, 2010:114–21 Omega-3 Fatty Acid Treatment for Aspirin Resistanceependence). Analyses were performed with SPSS version
1.0 statistical software (SPSS, Inc., Chicago, Illinois), and
tatistical significance was set at p  0.05.
esults
o achieve the pre-specified goal of 30 patients with aspirin
esistance (as defined by 2 of 3 criteria), screening of 485
atients was required (aspirin resistance rate of 6.2%) (Fig.
). Patients with aspirin resistance had similar clinical
haracteristics to those of aspirin-responsive patients, except
or a higher proportion of women among resistant patients
33.3% vs. 16%, p  0.02) (Table 1). Patients with aspirin
esistance were also treated with similar medications to
spirin-responsive patients (Table 1). It should be noted
hat concomitant clopidogrel treatment was not contraindi-
ated. Among the 22 patients treated with clopidogrel, 2
ad an ARU 500, but neither satisfied any criteria for
spirin resistance and therefore did not enter the study
roups (they were also not included in the control group).
linical Characteristics and Concurrent MedicationsTable 1 Clinical Characteristics and Concurrent Medications
Aspirin-Resistant
(n  30)
Aspirin-Responsive
(n  455)
Age (yrs) 66 9 67 10
Women 10 (33)* 73 (16)*
BMI (kg/m2) 27 6 28 12
Diabetes 11 (37) 170 (37)
Hypertension 18 (60) 291 (64)
Hyperlipidemia 29 (97) 404 (89)
Current smoker 5 (17) 48 (11)
Prior MI 19 (63) 255 (56)
Prior CABG 11 (37) 149 (33)
Prior PCI 26 (87) 403 (89)
Medications
Aspirin 100 mg 29 (97) 421 (93)
Aspirin 75–81 mg 1 (3.3) 23 (5.1)
Aspirin 150–162 mg 0 11 (2.4)
Clopidogrel 0 22 (4.8)
Statins 29 (97) 404 (89)
Beta-blockers 21 (70) 321 (71)
ACE inhibitors/ARBs 19 (63) 266 (59)
Calcium-blockers 3 (10) 67 (15)
alues are mean  SD or n (%). *p  0.02.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; BMI  body mass
ndex; CABG  coronary artery bypass graft; MI  myocardial infarction; PCI  percutaneous
oronary intervention.
latelet Reactivity and Response to Aspirin in the Omega-3 Fatty Aersus Aspirin Groups at Baseline and After 30 Days of TreatmentTable 2 Platelet Reactivity and Respo se to Aspirin in the OmeVersus Aspirin Groups at Baseline and After 30 Days o
Omega Group
Baseline Post
VerifyNow Aspirin (ARU) 566 35 461 47
Aggregation 0.5-mg/ml AA (%) 19.1 7 13.4 5
Aggregation 5-mol/l ADP (%) 68 10 54.7 11
Aggregation 10-mol/l ADP (%) 77.1 7 65.6 11erifyNow Aspirin assay (Accumetrics).
AA  arachidonic acid; ADP  adenosine diphosphate; ARU  aspirin reaction units.latelet reactivity and response to aspirin in the study
roups. The 30 patients with aspirin resistance were ran-
omized to receive either omega-3 fatty acids (omega group,
 15) or aspirin 325 mg (aspirin group, n  15) for a
eriod of 30 days. Clinical characteristics and concomitant
edical treatment were similar among the 2 groups and did
ot significantly differ from the characteristics of the total
spirin-resistant cohort (presented in Table 1). In both the
mega and aspirin groups, significant reductions in platelet
ggregation and the VerifyNow Aspirin score were observed
fter 30 days of treatment (Table 2). Plasma levels of TXB2
ere also reduced in both groups after 30 days of treatment
57% relative reduction in TXB2 levels in the omega group,
nd a 40% decrease in the aspirin group) (Fig. 2). Compar-
son of the magnitude of reductions in platelet reactivity and
XB2 levels between the 2 groups revealed that there were
o significant intergroup differences, except for a trend for
ifference in 10-mol/l ADP-induced platelet aggregation,
ith greater reduction in the omega group (relative reduc-
ion of 14.9% in the omega group vs. 6.9% in the aspirin
roup, p  0.06) (Fig. 3).
ates of aspirin resistance after treatment. After 30 days
f treatment with omega-3 fatty acids, 3 patients (20%)
emained resistant to aspirin (2 of 3 criteria), and 4 other
atients fulfilled only 1 criterion for aspirin resistance (3 of
hem had ADP-induced aggregation 70%, and 1 had
A-induced platelet aggregation 20%). In the aspirin
roup after 30 days of treatment with aspirin 325 mg,
patients (26.7%) were still resistant to the effects of
spirin, and 5 other patients fulfilled 1 criterion for aspirin
esistance (all had ADP-induced aggregation70%). Thus,
0% of the patients in the omega group and 73% of the
atients in the aspirin group were no longer resistant to
spirin, according to the definition employed in our study.
afety. During the 30-day treatment period no bleeding
pisodes were reported in either group. One patient treated
ith omega-3 fatty acids reported belching for a few days
hat subsided gradually and did not require discontinuation
f the drug.
ollow-up phase. Twenty-four patients (12 in each group)
articipated in this phase—performed approximately 1 year
fter the treatment period. As shown in Figure 4, in both
roups platelet aggregation in response to AA and ADP
ncreased significantly after discontinuation of the corre-
Fatty Acid
atment
Aspirin Group
p Value Baseline Post p Value
0.0001 554 19 476 57 0.0003
0.003 18.9 7 13 6 0.01
0.0005 66.3 6 56.7 6 0.0002
0.002 74.7 6 69.5 6 0.007cidga-3
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o the baseline levels (in both groups there were no
ignificant differences between the baseline and follow-up
evels in any of the aggregation assays). Similar findings
ere noted with the VerifyNow Aspirin assay (data not
hown).
ontrol group. The control group consisted of 15 patients
ho had a VerifyNow ARU 500 but did not satisfy
riteria for aspirin resistance. The purpose of the control
roup was to examine whether there is significant variability
n response to aspirin over a 30-day period, without any
hange in medical treatment. In contrast to the study
roups, there were no significant differences in platelet
ggregation or VerifyNow score between the baseline and
0-day measurements in the control group (Table 3).
Figure 2 Plasma TXB2 Levels at Baseline and After 30 Days of
Plasma thromboxane B2 (TXB2) levels at baseline and after 30 days of treatment
groups a significant reduction was noted from baseline after 30 days of treatment
with a p  0.045 in the aspirin group). There were no significant differences betw
Figure 3 Comparison of the Relative Reductions From Baseline
Comparison of the magnitude of relative reductions from baseline to post-treatmen
between the omega group and the aspirin group. There were no significant differen
adenosine diphosphate (ADP)-induced platelet aggregation in the omega group (p iscussion
o our knowledge, this is the first study that examined
otential therapeutic approaches to manage resistance to the
ntiplatelet effects of low-dose aspirin. Two approaches were
valuated: addition of omega-3 fatty acids or aspirin dose
scalation (to 325 mg daily). We identified 30 patients with
table CAD who were aspirin resistant, on the basis of AA and
DP-induced platelet aggregation and the VerifyNow Aspirin
ssay criteria. These patients were randomized to receive 1 of
he 2 treatment protocols for 30 days. Both therapeutic
pproaches were associated with a reduction in platelet
ggregation, VerifyNow Aspirin score, and plasma TXB2
evels and therefore with improved response to aspirin. In
ddition, the majority of patients treated by both treatment
tment
mega-3 fatty acids (omega group) or 325 mg of aspirin (aspirin group). In both
relative reduction with p  0.02 in the omega group, and 40% relative reduction
e groups at baseline or after treatment.
ost-Treatment in the 2 Groups
latelet aggregation (Aggr) and the VerifyNow Aspirin assay (Accumetrics) score
etween the 2 groups, except for a tendency for greater reduction in 10-mol/l
). AA  arachidonic acid.Trea
with o
(57%
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he criteria employed in our study.
spirin-resistance rate. The prevalence of aspirin resis-
ance found in our study (6.2%) is similar to that reported by
um et al. (4) in patients with stable cardiovascular disease
5.2%). Both studies employed similar criteria for definition
f aspirin resistance, although we also incorporated the
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Figure 4 Platelet Aggregation at Baseline, After Treatment, an
Platelet aggregation in response to arachidonic acid (AA) and adenosine diphosph
points: (A) baseline—low-dose aspirin (solid bars); (B) after 30 days of treatment
bars); and (C) low-dose aspirin—after discontinuing the corresponding treatment r
decreased after treatment and increased back to levels similar to the baseline leverifyNow Aspirin assay. Previous studies that reported 3igher rates of aspirin resistance (12% to 30%) studied
omewhat different patient populations, such as patients
ndergoing PCI (5,6), and/or used different criteria for
spirin resistance (e.g., only the VerifyNow Aspirin assay)
6,7). Lower rates of aspirin resistance (1% to 6%) were
eported when using only AA-induced platelet aggregation
s the criteria for resistance (14) and/or testing the effects of
puorg niripsA
Aspirin group
puorg niripsA
DP
 ADP P=0.02
P=0.01
P=0.01
ing Follow-Up
P) in the omega and aspirin groups (12 patients in each group) at 3 time
he corresponding regimen—omega-3 fatty acids or high-dose aspirin (gray
ns for at least 1 week (open bars—follow-up phase). In both groups, aggregation
er discontinuing the treatment regimens (p values for B vs. C time points).AA
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spirin-responsive patients, is consistent with previous stud-
es (4,6,13). Higher rates of aspirin resistance among
omen might contribute to the recently reported failure of
spirin to reduce the risk of a first MI in women, in contrast
o its beneficial primary prevention effects in men (22).
spirin dose effect. Considerable research has been dedi-
ated to study the dose-effect relationship of aspirin. In the
ntithrombotic Trialists’ Collaboration, a meta-analysis
hat included more than 200,000 patients, low-dose aspirin
as associated with proportional risk reduction of vascular
vents similar to that of high-dose aspirin but with fewer
astrointestinal side effects and less bleeding (12). Further-
ore, previous studies have shown that aspirin at low daily
oses of 50 to 100 mg is an effective antithrombotic agent
hat generally causes efficient inhibition of COX-1 as
emonstrated by 95% inhibition of serum TXB2 (23,24).
owever, Hart et al. (25) reported an incremental reduction
n serum TXB2 levels with increasing doses of aspirin (81,
25, or 1,300 mg). In the ASPECT (Aspirin Induced
latelet Effect) study, Gurbel et al. (14) reported that
ose-dependent effects of aspirin (81, 162, and 325 mg)
ere assay-dependent and were observed when using assays
uch as collagen- and ADP-induced platelet aggregation,
FA-100, and urinary 11-dehydroTXB2 but not AA-based
ssays. Therefore, although these studies indicate aspirin
ose-response with respect to TXB2 synthesis (14,25), there
oes not seem to be a clear and consistent dose-effect
elationship for aspirin, as assessed by platelet inhibition or
linical outcomes. This is in apparent disagreement with our
tudy, which showed improved response to aspirin when
ncreasing the dose from a low dose (75 to 162 mg) to 325 mg.
owever, in contrast to previous studies, we examined the
ffect of dose escalation only in patients with aspirin resistance,
hich might be a unique state. Lee et al. (13) have shown that
ow aspirin doses (100 mg) were associated with an increased
revalence of aspirin resistance compared with higher doses.
lthough the mechanisms for aspirin resistance are probably
ultiple and have not been well-established (24,26), in
ome cases there might be a contribution of reduced
ioavailability of aspirin (e.g., reduced absorption) (26) or of
ncreased platelet turnover and platelet hyper-reactivity
24,26,27). In both circumstances—reduced drug bioavail-
bility, and increased platelet turnover—an increase in the
ose of aspirin might be associated with better inhibition of
latelet Reactivity at Baselinend After 30 Days in the Co trol GroupTable 3 Platelet Re ctivi y at Baselineand After 30 Days in the Control Group
Baseline 30 Days
VerifyNow Aspirin (ARU) 519 16 513 19
Aggregation 0.5-mg/ml AA (%) 9.1 3 9.5 2.5
Aggregation 10-mol/l ADP (%) 64.5 10 61.9 9
Aggregation 5-mol/l ADP (%) 51.6 12 52.8 10
erifyNow Aspirin assay (Accumetrics).
Abbreviations as in Table 2.ts target—platelet COX-1. vffect of omega-3 fatty acids on response to aspirin. Treat-
ent of aspirin-resistant patients with omega-3 fatty acid
upplementation was associated in our study with improved
esponse to aspirin and reduced platelet reactivity, at least as
ffective as that achieved by increasing the aspirin dose. The
echanism of action probably involves a reduction in the
vailability of platelet membrane AA, along with an increase in
PA, which can compete with AA as a substrate of the
OX-1 pathway (15,16). The increased ratio of EPA to AA
ikely leads to a reduction in thromboxane A2 formation from
A (15,16). Indeed, we have observed a 56.8% relative
eduction in plasma TXB2 levels when omega-3 fatty acids
ere added to low-dose aspirin for 30 days. These results are
upported by the study of Engström et al. (28), who showed
hat in 4 healthy volunteers addition of fish oil to low-dose
spirin augmented the inhibition of serum TXB2 by aspirin.
arson et al. (19) have also reported that omega-3 fatty acids
nhance the antiplatelet effects of aspirin (measured by platelet
ggregation) in healthy volunteers. We extended these find-
ngs to patients with aspirin resistance. It should be empha-
ized that the addition of omega-3 fatty acids (1 to 4 g/day)
o aspirin in cardiovascular patients has not been associated
ith an increased risk of bleeding (20,21). Furthermore,
mega-3 fatty-acid supplementation might have favorable
ffects in the secondary prevention of CAD and its compli-
ations (21,29,30). Taken together, the clinical and platelet
unction studies suggest that omega-3 fatty-acid supple-
entation might be a promising approach to optimize
esponse to aspirin.
tudy limitations. First, although we attempted to verify
ompliance to aspirin and the treatment regimens before
nd during the study, by several measures, we cannot
bsolutely rule out inadequate compliance. Second, unlike
he 2 study groups, the control group did not consist of
atients with aspirin resistance but rather patients with a
erifyNow Aspirin score 500 ARU who did not satisfy
spirin resistance criteria. Therefore, it is not a “classic”
atched control group. However, it does indicate that in
atients with stable CAD treated with low-dose aspirin
here were no significant changes in the measured platelet
ndexes over a 30-day period. Therefore, the reductions in
latelet reactivity and TXB2 levels we observed in the study
roups are likely not the result of “spontaneous” fluctuations
ver time but are related to the effects of the therapeutic
egimens given. Finally, the study groups are of relatively
imited size for inter-group comparisons.
onclusions and Clinical Implications
here is accruing evidence that resistance to the antiplatelet
ffects of aspirin is associated with an increased risk of
dverse cardiovascular events (2,4–7,9–11). However, cur-
ently there is no established therapeutic approach to
anage and overcome aspirin resistance in patients treated
ith low dose of the drug. We have demonstrated by usingarious platelet assays that either adding omega-3 fatty acids or
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January 12, 2010:114–21 Omega-3 Fatty Acid Treatment for Aspirin Resistancencreasing the aspirin dose can improve response to aspirin and
educe residual platelet reactivity in stable patients with CAD.
reatment with both regimens was associated with a reduction
n aspirin-resistance rates. We did not examine the clinical
mpact of such therapeutic interventions or the impact of
outine monitoring of aspirin response. Further larger studies
re required to assess whether our findings can be translated to
clinical benefit in patients with cardiovascular disease found
o be resistant to aspirin and treated with the therapeutic
egimens tested in our study.
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